We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
Read MoreHide Full Article
Sanofi (SNY - Free Report) has announced its entry into a collaboration and license agreement with UK-based pharmatech company, Exscientia plc (EXAI - Free Report) , whose AI-driven platform it plans to use in order to develop up to 15 small-molecule candidates targeting oncology and immunology.
With this deal, Sanofi is looking to leverage Exscientia’s AI-based capabilities and personalized medicine platform to develop precision-engineered medicines for cancer and immune-mediated diseases. The collaboration aims to accelerate drug discovery and improve clinical success.
Per the agreement, Sanofi will make an upfront cash payment of $100 million to Exscientia, who will also be entitled to receive potential development, regulatory and commercial milestone payments worth up to $5.2 billion. Exscientia will also be eligible to receive tiered royalties on net sales if a product is commercialized from the collaboration.
In 2019, Sanofi in-licensed Exscientia’s novel bispecific small-molecule candidate targeting inflammation and immunology. Sanofi and Exscientia have been working together since 2016.
Shares of Sanofi have risen 4.4% in the past year compared with the industry’s growth of 16.8%.
Image Source: Zacks Investment Research
Sanofi has been actively seeking acquisitions and deals for boosting its pipeline and driving growth.
In December 2021, Sanofi entered into an agreement to acquire privately-held immuno-oncology company, Amunix Pharmaceuticals, for an upfront payment of approximately $1 billion.
The acquisition of Amunix will add potentially transformative cancer therapies and three technology platforms to Sanofi’s pipeline. Amunix’s proprietary masking technology platform, XTEN, will help Sanofi develop safer and more efficacious cancer drugs by activating preferentially in disease-specific micro-environments.
Sanofi acquired biopharma company Kadmon Holdings in November 2021, adding an FDA-approved treatment for chronic graft-versus-host to its portfolio.
In September 2021, Sanofi acquired its long-time partner Translate Bio for approximately $3.2 billion. The acquisition added to Sanofi’s portfolio a promising mRNA technology platform to develop therapeutics and vaccines and also accelerate the development of their existing partnered pipeline programs. Sanofi also acquired two clinical-stage biopharmaceutical companies, Kiadis and Kymab, in 2021. These acquisitions added natural-killer cell therapies, and immune and inflammatory candidates to its pipeline.
We expect to see more such activities on the acquisition and collaboration front.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include Pfizer Inc. (PFE - Free Report) and AbbVie Inc. (ABBV - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer’s earnings estimates have been revised 44.6% upward for 2022 over the past 60 days. The stock has rallied 47.6% in the past year.
Pfizer’s earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
AbbVie’s earnings estimates have been revised 0.7% upward for 2022 over the past 60 days. The stock has increased 23.7% in the past year.
AbbVie’s earnings have surpassed estimates in three of the trailing four quarters and matched the same on the other occasion.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
Sanofi (SNY - Free Report) has announced its entry into a collaboration and license agreement with UK-based pharmatech company, Exscientia plc (EXAI - Free Report) , whose AI-driven platform it plans to use in order to develop up to 15 small-molecule candidates targeting oncology and immunology.
With this deal, Sanofi is looking to leverage Exscientia’s AI-based capabilities and personalized medicine platform to develop precision-engineered medicines for cancer and immune-mediated diseases. The collaboration aims to accelerate drug discovery and improve clinical success.
Per the agreement, Sanofi will make an upfront cash payment of $100 million to Exscientia, who will also be entitled to receive potential development, regulatory and commercial milestone payments worth up to $5.2 billion. Exscientia will also be eligible to receive tiered royalties on net sales if a product is commercialized from the collaboration.
In 2019, Sanofi in-licensed Exscientia’s novel bispecific small-molecule candidate targeting inflammation and immunology. Sanofi and Exscientia have been working together since 2016.
Shares of Sanofi have risen 4.4% in the past year compared with the industry’s growth of 16.8%.
Sanofi has been actively seeking acquisitions and deals for boosting its pipeline and driving growth.
In December 2021, Sanofi entered into an agreement to acquire privately-held immuno-oncology company, Amunix Pharmaceuticals, for an upfront payment of approximately $1 billion.
The acquisition of Amunix will add potentially transformative cancer therapies and three technology platforms to Sanofi’s pipeline. Amunix’s proprietary masking technology platform, XTEN, will help Sanofi develop safer and more efficacious cancer drugs by activating preferentially in disease-specific micro-environments.
Sanofi acquired biopharma company Kadmon Holdings in November 2021, adding an FDA-approved treatment for chronic graft-versus-host to its portfolio.
In September 2021, Sanofi acquired its long-time partner Translate Bio for approximately $3.2 billion. The acquisition added to Sanofi’s portfolio a promising mRNA technology platform to develop therapeutics and vaccines and also accelerate the development of their existing partnered pipeline programs. Sanofi also acquired two clinical-stage biopharmaceutical companies, Kiadis and Kymab, in 2021. These acquisitions added natural-killer cell therapies, and immune and inflammatory candidates to its pipeline.
We expect to see more such activities on the acquisition and collaboration front.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include Pfizer Inc. (PFE - Free Report) and AbbVie Inc. (ABBV - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer’s earnings estimates have been revised 44.6% upward for 2022 over the past 60 days. The stock has rallied 47.6% in the past year.
Pfizer’s earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
AbbVie’s earnings estimates have been revised 0.7% upward for 2022 over the past 60 days. The stock has increased 23.7% in the past year.
AbbVie’s earnings have surpassed estimates in three of the trailing four quarters and matched the same on the other occasion.